** Shares of telehealth company Mangoceuticals , also known as MangoRx, fall 4% to $2.43 before the bell
** Eli Lilly sues three medical spas and online vendors, including MangoRx, for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss drug Zepbound
** Earlier this month, MangoRx launched its own brand called "Trim" - a compounded, oral dissolvable tirzepatide tablet
** Lilly said MangoRx was selling an oral version despite the lack of any study showing that formulation to be safe and effective
** MangoRx also sells "Slim", its oral compounded formulation of semaglutide, the active ingredient in Novo Nordisk's Wegovy
** MangoRx did not immediately respond to a request for comment
** As of last close, MGRX down nearly 42% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。